Observations that make me uncomfortable, page-9

Depends on what you are looking for/reading into I suppose, I still go back to the original conversations I had with Pete Smith (PhD) and his meticulous approach to analysis of data. He is a scientist and great at analysing the backing the scientific data, albeit he made wrong management decisions, he was the one who convinced me of the data (and also helped me analyse/understand other companies data also to see what to invest in - which to date he has always been correct on). He spent days analysing other competitors data, research papers and other relevant information to ensure that we had a great PLATFORM to help other people, that he was convinced on.

Not long until time will tell how this all plays out.

However as another example:

https://investor.lilly.com/releasedetail.cfm?ReleaseID=870557

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen

INDIANAPOLIS, Sept. 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.  The global, randomized, double-blind study compared ramucirumab plus FOLFIRI to placebo plus FOLFIRI as a second-line treatment in patients with mCRC after treatment with bevacizumab, oxaliplatin and a fluoropyrimidine in the first-line setting.

The key thing here is that they are targeting a different segment of the market - as from what I have read they are limiting this drug to be a 2nd line treatment depending on what you had from the 1st line treatment.

"compared to placebo and FOLFIRI as a second-line treatment in patients with mCRC who have progressed on or after first-line treatment with bevacizumab, oxaliplatin and a fluoropyrimidine"

Side effects don't look very nice either:

IMPORTANT SAFETY INFORMATION FOR CYRAMZA

	Column 1
0	WARNING: HEMORRHAGE CYRAMZA increased the risk of hemorrhage, including severe and sometimes fatal hemorrhagic events. Permanently discontinue CYRAMZA in patients who experience severe bleeding.